The SardiNIA Project

For the Project (called Progenia for the Sardinian public), this poster shows one of the participants , who lived to over 100 through a vigorous old age

 For the Project (called Progenia for the Sardinian public), this poster shows one of the participants , who lived to over 100 through a vigorous old age

Welcome to SardiNIA Project

Finding longevity genes is only one of many goals for gerontologists. An equally important mission is unraveling the genetic processes involved in age-related traits and diseases. NIA and Italian investigators are focusing their attention on the Mediterranean island of Sardinia. Why? We quote directly from the rationale and background for the initiation of the study in 2001, which also apply to follow-up studies in the course of the Project:

To identify genetic bases for prominent age-associated changes, including cardiovascular risk factors and determinants of personality traits, in a founder population. The results of the study will extend the studies of aging-associated conditions of outbred populations.

Recent reports form the Baltimore Longitudinal Study on Aging (BLSA) and other population studies have identified some epidemiological and genetic risk factors for aging-associated diseases; but the majority of studies have been observational, determining the range of values for a phenotype as a function of aging. These analyses have been increasingly supplemented in recent years by genetic studies based on powerful genome-wide association studies in numerous general populations. Nevertheless, considerable attention has focused on the promise of 'founder populations' for the simplification of analysis of complex traits and aging-related diseases. Such rare populations arise from a delimited group living in a defined region for many centuries with minimal admixture from outside populations. The Sardinian population is one of the few that is both numerous and accessible enough, and one of the most extreme in its relative lack of heterogeneity. It can thus be studied for a wide variety of both frequent and relatively rare traits. The targeted region for the present study, Ogliastra, has a particularly isolated population of 60,000, in an area enclosed by two mountain ranges and the sea; and for the study of diseases, the entire catchment of 1,500,000 Sardinians across the island can furnish enough cases and controls to investigate genetic factors for a wide range of conditions and maladies.

The SardiNIA study has now decisively established that analyses on the island can indeed help to analyze both complex traits and diseases, often providing information that was difficult or impossible to obtain in other population studies.

Concerning the choice and progress of the Project, its positive features include

    • Relatively constant environment (in rural towns for the core study)
    • High level of altruism and interest in sharing genetic patrimony
    • Support of the local Bishop, Mayors, and Health Authorities
    • Local clinic location that facilitates rapid and repeated visits: e.g., 3,500 were recalled in 1 year for fractionation of white cells into 95 subtypes within 90 min of blood draw, and for a subsequent second blood draw to extend studies to B cells and cytokines.
    • Structures of more than 1,000 families embedded in a large cohort of individuals, permitting accurate estimates of genetic heritability.
    • Lower cost sequencing and genotyping coverage: 2,000 individuals sequenced at 4-fold coverage yielded the imputed DNA sequence for 7,000 in the cohort.
    • Reliable detection of rare DNA sequence variants Assessment of diagnostic/prognostic strength of genetic factors in a longitudinal study with medical outcomes.
    • Analysis of mitochondrial variation and its transmission.
    • Straightforward formulation and testing of imputation algorithms.
    • Excellent coverage of genetic variation in Europe.
    • Easier discovery of interactions/pleiotropy of traits.

In a first survey, the project team recruited over 6,100 subjects from a catchment area including four towns in east-central Sardinia and assessed a first list of >200 traits. The baseline survey has been followed by follow-up visits that collected longitudinal data on the same traits collected at baseline but added assessment of frailty-related traits, namely measures of bone density and geometry, muscle strength, and gait speed, and additional cardiovascular measures (see below). In the course of SardiNIA3, along with the expansion of the cohort and the addition of more traits (see below), increases in testing efficiency and additional cost-sharing funds from Sardinian sources permit the completion of Fourth Visits for the entire cohort. Also in current actions, DNA sequencing has recovered essentially all of the genetic variation in the cohort, and further arrangements for an Outcome Study have also been made to be implemented in “SardiNIA4”, a further 5-year continuation of the Project that also projects Fifth Visits for the cohort.

The infrastructure for the clinic and phenotypic testing has been stable, with stringent quality control, which is reflected in the high quality of the database. The initial sample cohort included over 62% of the eligible population living in the region (age 14-102 years), and at least 96% of the initial cohort have all grandparents born in the same province. The initial group included 4,933 phenotyped sib pairs, 4,266 phenotyped parent-child pairs, >4,069 phenotyped cousin pairs, and >6,459 phenotyped avuncular pairs. Additional recruitment has increased the cohort substantially, and results have consistently shown that for essentially every trait, most of the associated genes and variants would be involved in determining variance in both young and old and in men and women. Thus, genetic analyses can draw on data from all ages and both genders.

The added value of studying a founder population has also been demonstrated by the extension of DNA analysis to the full range of variation by sequencing. The population has proven to contain the great bulk of variation found in other populations, but during its isolation over many thousands of years, many variants rare elsewhere have risen to relatively high levels on the island – by drift or selection – and others have newly arisen as Sardinian-specific. These have provided extensive new information about a whole range of traits and pathways (e.g., Nature Genetics November, 2015 articles and Editorial).

Sardinia also offers a special entrée to the genetics of specific diseases that are especially prevalent in the founder population. This includes the anomalously high incidence of autoimmune diseases including Multiple Sclerosis and Type 1 diabetes, which interrupt the high to low gradient of incidence from Northern to Southern Europe. Again, this has fostered novel findings in causation and pathophysiology.

The founder population itself also contains within its DNA a record of human demography through history, which has permitted the inference of the timing of human population movements based on mitochondrial and Y chromosome analyses.

Regarding the course and mechanism of aging, the longitudinal study, now in its 15th year, focuses on residents of the cluster of towns to collect longitudinal information on more than 400 age-related quantitative traits ("endophenotypes" or "quantitative risk-related genetic or environmental factors") that can be scored on a continuous scale, as well as >200 dichotomous traits (including major diseases and risk factors such as smoking). The use of quantitative traits permits the study of the entire range of allelic variation in a population, with particular interest in a range of cardiovascular risk factors, anthropometric measurements, blood test values, facets of personality, and bone-density and frailty-related variables.

The longitudinal study of a broad range of phenotypes in a founder population is distinctive in this study, and stable environmental/epidemiological factors combined with the simplification of genetic analyses also aid in proposed joint investigations of relative risk. Furthermore, because we are collecting risk factor data, we can also analyze, in an Outcome Study, the prognostic power and/or pathophysiological relevance of earlier predictors for the onset of serious risk factors [e.g., increases in pulse wave velocity as a function of earlier (predictor) lipid and inflammatory markers].

Vulnerability Disclosure Policy